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ABSTRACT
Objectives To describe the relations between baseline 
clinical characteristics of the Applied Public- Private 
Research enabling OsteoArthritis Clinical Headway (IMI- 
APPROACH) participants and their predicted probabilities 
for knee osteoarthritis (OA) structural (S) progression and/
or pain (P) progression.
Methods Baseline clinical characteristics of the 
IMI- APPROACH participants were used for this study. 
Radiographs were evaluated according to Kellgren and 
Lawrence (K&L grade) and Knee Image Digital Analysis. 
Knee Injury and Osteoarthritis Outcome Score (KOOS) 
and Numeric Rating Scale (NRS) were used to evaluate 
pain. Predicted progression scores for each individual 
were determined using machine learning models. Pearson 
correlation coefficients were used to evaluate correlations 
between scores for predicted progression and baseline 
characteristics. T- tests and χ2 tests were used to evaluate 
differences between participants with high versus low 
progression scores.
Results Participants with high S progressions score 
were found to have statistically significantly less 
structural damage compared with participants with low S 
progression scores (minimum Joint Space Width, minJSW 
3.56 mm vs 1.63 mm; p<0.001, K&L grade; p=0.028). 
Participants with high P progression scores had statistically 
significantly more pain compared with participants with 
low P progression scores (KOOS pain 51.71 vs 82.11; 
p<0.001, NRS pain 6.7 vs 2.4; p<0.001).
Conclusions The baseline minJSW of the IMI- APPROACH 
participants contradicts the idea that the (predicted) course 
of knee OA follows a pattern of inertia, where patients 
who have progressed previously are more likely to display 
further progression. In contrast, for pain progressors the 
pattern of inertia seems valid, since participants with high 
P score already have more pain at baseline compared with 
participants with a low P score.
INTRODUCTION
One of the major challenges in knee osteo-
arthritis (OA) clinical trials is the selection 
of patients. Because actual cure is not antic-
ipated, patients who will sufficiently progress 
without intervention are needed to provide 
an opportunity to observe arrest or reduction 
of disease progression. The Food and Drug 
Administration and European Medicines 
Agency still define OA progression by radi-
ographic joint space narrowing (structural 
progression) and by progressive or sustained 
significant pain (pain progression).1 2 Since 
progression in OA is on average (very) slow, 
without preselection of fast progressive 
patients, clinical trials require large group 
sizes and long follow- up. The course of 
knee OA might follow a pattern of inertia, 
Key messages
What is already known about this subject?
 ► The Applied Public- Private Research enabling 
OsteoArthritis Clinical Headway (APPROACH) cohort 
study is a 2- year observational study using a unique, 
multistep selection of participants, to include people 
with an increased likelihood of structural progres-
sion and/or pain progression.
What does this study add?
 ► This study provides the clinical characteristics (de-
mographics, radiographic features and pain severity) 
of the selected patients in the IMI- APPROACH pro-
spective cohort in relation to their scores for pre-
dicted structural progression and pain progression.
How might this impact on clinical practice or 
further developments?
 ► In the IMI- APPROACH cohort, patients who have 
experienced structural progression previously are 
less likely to display further structural progression, 
whereas participants that already have more pain 
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meaning that knees that are progressing are more likely 
to continue to progress, and stable knees are more likely 
to remain unchanged.3 Unfortunately, at the moment of 
inclusion in a clinical trial, it is usually not known how 
the OA progressed in the years previous to inclusion and 
with that progression during the trial period is difficult 
to predict.
Despite efforts over the past decades to develop 
markers of disease, imaging procedures and biochem-
ical marker analyses need to be improved and possibly 
extended with more specific and sensitive methods 
to reliably describe disease processes, to diagnose the 
disease at an early stage, to classify patients according to 
their prognosis and to follow the course of disease and 
treatment effectiveness. The Innovative Medicines Initia-
tive - Applied Public- Private Research enabling OsteoAr-
thritis Clinical Headway (IMI- APPROACH) consortium 
has set up a broad database of different OA patients and 
a longitudinal cohort to combine conventional and new 
disease markers, and identify different OA phenotypes. 
The APPROACH cohort study is a 2- year observational 
study using a unique, multistep selection of participants, 
to include people with an increased likelihood of struc-
tural progression and/or pain progression.4 Structural 
progression was defined as a reduction in Joint Space 
Width (JSW) of ≥0.3 mm per year over a period of 2–3 
years (0.7 mm has been described as the minimal detect-
able difference in radiographic JSW).5 Pain progression 
was defined as at least one of the three following: Knee 
Injury and Osteoarthritis Outcome Score (KOOS) pain 
(on a 0–100 point scale; 100 being the worst) increase ≥5 
points/year with a pain level ≥40 at 2 years, or KOOS 
pain increase ≥10 points/year with a pain level ≥35 at 
2 years or a pain level ≥40 at both baseline (BL) and 
2 years. The participants were selected from existing 
OA cohorts (CHECK (Cohort Hip & Cohort Knee),6 
HOSTAS (Hand OSTeoArthritis in Secondary care),7 
MUST (Musculoskeletal pain in Ullensaker STudy),8 
PROCOAC (PROspective COhort of A Coruña)9 and 
DIGICOD (DIGItal COhort Design)),10 or from outpa-
tient departments (in case the original cohort did not 
provide sufficient participants. As a first step, historical 
data were used to train machine learning (ML) models to 
provide a S(tructural) and P(ain) progression score for 
each individual, reflecting the probability to become a 
‘progressor’ on these outcomes.4 So the S and P progres-
sion score represent throughout the manuscript the 
predicted progression, not the actual progression. These 
predicted progression scores were combined into one 
ranking score which orders patients by the likelihood 
of progression in general, throughout the manuscript 
described as ranking score. Participants with the highest 
rank were selected for a screening visit and ranked again 
using collected up- to- date information on disease status 
(demographics, radiographs and questionnaires). Then 
75% of the screened participants with the highest rank 
(most likely to progress) were included in the study. As 
a consequence, each included participant was assigned 
a S progression score, P progression score and a ranking 
score.
The predictions of the final ML model are based 
on cross- sectional data of patients at the moment of 
or shortly before inclusion in the cohort, viz. BL data. 
Participants are subsequently followed for 2 years which 
is at present ongoing, to study actual progression with 
the use of a large number of conventional and explor-
atory measures. Irrespective of the actual progression, 
this analysis provides the clinical characteristics (demo-
graphics, radiographic features and pain severity) of the 
selected patients in the IMI- APPROACH prospective 
cohort in relation to their S progression, P progression 
and ranking score. The present study provides insight 
in the actual values of these BL parameters, and with 




In this analysis, all included participants (n=297) of the 
IMI- APPROACH study were used. The study protocol 
and the general cohort profile have been described 
previously.11 Age (mean 66.5 years, SD 7.1), body mass 
index (BMI) (mean 28.1, SD 5.3), sex (female/male ratio 
230/67, and ethnicity (Caucasian/white, black/African 
American, Asian or other) as well as structural damage 
and pain were included in the current analyses.
Evaluation of structural damage
Posterior–anterior weight- bearing semiflexed knee radi-
ographs were obtained according to the protocol of 
Buckland- Wright et al.12 These radiographs were graded 
according to Kellgren and Lawrence (K&L grade)13 and 
evaluated by Knee Image Digital Analysis.14 Minimum 
JSW (minJSW) in mm, osteophyte area (mm2), and 
subchondral bone density (mm Aluminium Equivalents; 
Alu Eq.) were used for analyses.
Pain evaluation
Pain was evaluated using a Numeric Rating Scale (NRS) 
and the pain subscore of the KOOS.15 This subscore is 
calculated from nine questions, each with a 5- point Likert 
scale. It is normalised to a 0–100 range, where 0 means 
maximal limitations (maximal pain) and 100 means no 
limitations (no pain).
Statistical analysis
IBM SPSS Statistics V.25.0.0.2 was used for statistical 
analysis. BL data are presented in relation to the S 
progression, P progression and final ranking score. 
Pearson correlation coefficient was used to determine 
correlations between progression/ranking scores and 
clinical, structural and demographic variables. Correla-
tions were considered weak when r<0.3, moderate when 
0.3≥r <0.5, and strong when r≥0.5. Additionally, patients 
were partitioned into three equal size groups (tertiles) 
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clinical, structural and demographic characteristics were 
compared between patients with lowest (one- third) or 
highest (one- third) scores using T- test (continuous vari-
ables) or χ2 test (categorical variables). For all tests, a 
p<0.05 was considered statistically significant.
RESULTS
Figure 1 shows the individual S and P progression scores 
of all 297 participants.
BL characteristics of participants with lowest and 
highest S progression, P progression or ranking scores are 
presented in table 1. Additional graphical representation 
of the relationships between S progression, P progression 
and ranking score and age and BMI are shown in online 
supplemental figure S1 (age) and online supplemental 
figure S2 (BMI). For majority of the characteristics, the 
differences between participants with the highest and 
lowest S progression, P progression or ranking scores 
are statistically significant. Age was higher in partici-
pants with the lowest S progression scores compared 
with participants with the highest S progression scores 
(p=0.029). The same trend was found for P progression 
scores, although not statistically significant. There was 
no difference in BMI for the S progression scores. The 
difference in osteophyte area was statistically significant 
different only for the P progression scores.
Figure 2 shows the correlations between different 
progression scores (S progression, P progression and 
ranking score) and BL minJSW. A moderate posi-
tive correlation of the ranking score with minJSW was 
observed (r=0.395, p<0.001). The S progression score 
strongly positively correlated with minJSW (r=0.646, 
p<0.001), whereas the P progression score only weakly 
negatively correlated with minJSW (r=−0.197, p=0.001). 
The participants with the highest ranking scores had a 
statistically significant higher minJSW compared with 
participants with the lowest ranking scores (3.08 mm 
vs 2.14 mm, p<0.001). The same was observed for the 
S progression scores (3.56 mm vs 1.63 mm, p<0.001). 
In contrast, participants with the highest P progres-
sion scores had a statistically significant lower minJSW 
compared with participants with the lowest P progression 
scores (2.29 mm vs 2.99 mm, p<0.001).
Figure 3 shows the correlations between the different 
progression scores (S progression, P progression and 
ranking score) and BL KOOS pain. A moderate positive 
correlation between ranking score and KOOS pain was 
observed (r=0.451, p<0.001). The P progression score 
correlated strongly positively with KOOS pain (r=0.697, 
p<0.001), whereas S progression score correlated weakly 
and negatively with KOOS pain (r=−0.212, p<0.001). 
Participants with the highest ranking scores had statisti-
cally significant more pain compared with participants 
with the lowest ranking scores (57.87 vs 75.87, p<0.001). 
The same was observed for P progression scores (51.17 vs 
82.11, p<0.001). In contrast, participants with the highest 
S progression scores had statistically significant less pain 
compared with participants with the lowest S progression 
scores (69.21 vs 60.23, p<0.001).
Distribution of K&L grades is presented in figure 4. In 
accordance with the correlation between the S progres-
sion score and minJSW, participants with the highest S 
progression scores had statistically significant lower K&L 
grades, compared with participants with the lowest S 
progression scores. For ranking score and P progression 
score K&L grade was not statistically significantly different 
between groups (p=0.347 and p=0.106, respectively).
The analysis of ethnicity is presented in figure 5. The 
difference was statistically significant only for P progres-
sion scores (7.1% vs 1.0%). For ranking score and S 
progression score, ethnicity was not statistically signifi-
cantly different between groups (p=0.733 and p=0.052, 
respectively).
Figure 1 Combined distribution of the S progression and P 
progression scores of all participants.
Solid lines indicate median values of S progression score 
(0.391) and P progression score (0.407). Dotted lines indicate 
tertile borders (0.367 and 0.425 for S score, 0.259 and 0.540 
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DISCUSSION
Within the IMI- APPROACH cohort study, a higher S 
progression score implicates a higher likelihood for struc-
tural progression. According to the general perception 
that the course of knee OA follows a pattern of inertia, 
participants with a higher S score were expected to have 
lower minJSW (since progression already happened 
before inclusion). However, in our analysis, the opposite 
was observed and participants with a high S progression 
score, had a statistically significantly higher minJSW and 
lower K&L grade, compared with participants with a low 
S progression score. In contrast, Halilaj et al found no 
differences in BL characteristics, including JSW, between 
Figure 2 Relationship between minJSW and progression/
ranking scores. The middle panels of each plot show 
correlation between minJSW and ranking score (A), S 
progression score (B), and P progression score (C). Each dot 
represents a single participant; dots in grey show the middle 
tertile of the score. Left and right boxplots show the score 
distribution (median value with 95% CIs) of the participants 
in the lowest (left) and highest (right) tertile of ranking score 
(A), S progression score (B) and P progression score (C). 
minJSW, minimum Joint Space Width.
Figure 3 Relationship between KOOS pain and 
progression/ranking scores. The middle panels of each plot 
show correlation between KOOS pain and ranking score 
(A), S progression score (B) and P progression score (C). 
Each dot represents a single participant; dots in grey show 
the middle tertile of the score. Left and right boxplots show 
the score distribution (median value with 95% CIs) of the 
participants in the lowest (left) and highest (right) tertile of 
ranking score (A), S progression score (B) and P progression 
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fast- progressors and non- progressors within the OA Initi-
ative (OAI) incidence cohort.16 17 The higher minJSW 
and lower K&L grade implicate presence of more carti-
lage that still can deteriorate, and therefore, provide an 
opportunity for structural progression. The ranking from 
the ML model reflects this.
For KOOS and NRS pain, the contrary was found. 
Participants with a high P progression score had more 
pain at BL compared with participants with a low P 
progression score. Again, in the OAI incidence cohort 
the contrary was found. Patients with improving WOMAC 
scores had more pain at BL, compared with patients with 
stable pain or patients with pain progression.17 The OAI 
incidence cohort included patients who were at high risk 
of developing OA during the study, while patients in the 
APPROACH cohort already had OA and were selected 
based on a high change for progression.
The likely explanation for our result lies in the definition 
of pain progression. While structural progression is solely 
based on JSW narrowing, the definition for pain progres-
sion was more complex, not only including progression 
but also high sustained pain over the past years. Although 
still speculative, most participants with a high P progres-
sion score may have been provided by patients with a 
high sustained score. Indeed, low pain scores reduced 
the probability of being a P progressor,4 supporting the 
idea of a pattern of inertia, but contrasting the window 
for change as observed for structure progression.
The ranking score, on which the patient selection was 
based, combines both progression scores using normali-
sation of the individual progression scores.4 Participants 
with a high ranking score had statistically significantly 
higher minJSW, lower K&L grade (contrasting inertia 
but providing a window for change), and more pain 
(according to the inertia concept but without the 
window for change regarding progression) compared 
with participants with a low ranking score. Although 
these BL characteristics seem to be counterintuitive, 
this combination provides potentially the best patient 
selection for treatment modalities that decrease pain 
(initially low KOOS score) and prevent, stop or slow- 
down structural progression (initially large JSW). With 
all present knowledge on treatment modalities thus far, 
this supports testing treatment modalities that are able 
to halt tissue structure damage and decrease pain. As 
cartilage structure repair is still challenging, this may 
turn out to be the best approach to patient selection for 
clinical trials.
The limited number of participants included in the 
study, made the IMI- APPROACH cohort difficult to 
compare different ethnicities within the non- Caucasian 
group. However, differences in pain severity were previ-
ously described between Non- Hispanic blacks and Non- 
Hispanic whites,18 19 and Asians and Caucasians.20
The main limitation of this analysis is the availability 
of only BL data. The predicted S, and P progression, 
and ranking scores used in this manuscript only repre-
sent the likelihood of becoming a progressor. The 
actual progression can only be evaluated when all 2- year 
follow- up data are available, and may enable fine- tuning 
or, when needed, correction of the BL predictive param-
eters. Nevertheless, the relationships between BL and the 
predicted progression, provides insights on clinical char-
acteristics of this unique cohort.
In conclusion, the selected IMI- APPROACH cohort 
consists of patients with high pain levels and low struc-
tural damage, suitable for evaluation of treatment modal-
ities that decrease pain and arrest or slow- down tissue 
structural damage.
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